GLP1R/GIPR co-agonist NNC0090-2746 tested in T2DM patients in a randomized, placebo-controlled, double-blind phase 2 trial, administered subcutaneously once a day, showed an important effect in glycemia control and diminished body weight, cholesterol levels, and leptin [76] (Table 1). Here, GIPR is linked to type 2 diabetes mellitus.